Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Article excerpt
Highlighted: the sentence this signal was extracted from
Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritis Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study This is the second of multiple studies planned to evaluate MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestones BOSTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has initiated a second Phase 2 clinical study for the VAV1-directed MGD MRT-6160 (DDY391) in people living with active moderate to severe psoriatic arthritis (PsA). The study follows the Phase 2 trial in Sjögren's disease initiated in August and is part of a global exclusive development and commercialization license agreement between Monte Rosa and Novartis to advance VAV1 MGDs, including MRT-6160 (DDY391). In connection with the first patient visit of the study, Monte Rosa will receive a $37.5 million milestone payment from Novartis. "This Phase 2 study will assess MRT-6160 in participants with active moderate to severe psoriatic arthritis, a disease with...
Keep reading with a free account
The rest of this article, and every signal for Novartis, is in your free account.